Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2019-07-02
Target enrollment:
Participant gender:
Summary
This is an open label, phase I study to test for maximum tolerated dose (MTD) or recommended
phase II dose (RP2D) of the combination of nivolumab and bevacizumab. The study will use a
3+3 phase I study design using a fixed dose of nivolumab (240mg) and escalating doses of
bevacizumab (1-10mg).